Regeneron and Sanofi announced European Commission approval of Dupixent® (dupilumab) for the treatment of children aged six months to five years old with severe atopic dermatitis. Dupilumab is the only targeted medicine to treat this condition in young children approved in Europe and the US. The approval was based on data from a phase III clinical trial published in the Lancet.
This comes after Regeneron and Sanofi recently announced that the FDA accepted their sBLA for Dupixent® (dupilumab) to treat chronic spontaneous urticaria.